Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in November 2021. Updated November 30, 2021.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Pathways’ Picks November 17: Big Week in Washington, Aussie Reclassifications, China Picks, and More
Unlocking the True Power of AI/ML-Based Medical Technology
Capitol Hill Staffers are Impatient for Device User Fee Deal
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to MedTech Strategist & Market PathwaysStart Trial
While the first generation of bioresorbable stents aims to enhance the treatment of peripheral artery disease with temporary support, STENTiT is on to the next generation with a platform of resorbable devices that promise to do what no stent can: elicit natural regeneration of the artery.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.Learn More
The five most-read MedTech Strategist articles posted in October to MyStrategist.com: ShangBay Capital's approach to medtech investing, Glenn Snyder and Paul Grand discuss findings from the recent MedTech Innovator/Deloitte survey on medtech start-up trends, highlights from NASS 2021, and near-term opportunities in the neural interface field.